How to target the treatment of renal cancer metastasis

The effects of chemotherapy and radiotherapy on metastatic renal cell carcinoma are not good, and immunotherapy is also unsatisfactory with an efficacy of only 10% to 20%. The emergence of targeted therapy in recent years has brought new hope for the treatment of metastatic renal cancer. So, what are the techniques for using targeted therapy? Let's take a look at the following introduction.

How to treat renal cancer metastasis in a targeted manner is described below:

The current first-line treatment drug is sunitinib. The standard regimen is 50 mg per day for 28 days, followed by a 14-day break. However, more than 50% of patients cannot tolerate this standard regimen. Retrospective data show that if the treatment dose is changed to control drug toxicity, the treatment effect is not ideal; in addition, disease progression may occur during the 14-day break period of the treatment regimen, indicating that a single dosing regimen is not suitable for all patients.

So, how should the drug be administered to achieve the greatest therapeutic effect and avoid unbearable toxic side effects? To this end, the American Society of Clinical Oncology (ASCO) reported a set of preliminary results of a retrospective study in 2015, hoping to provide an answer.

The study was conducted in such a way that all subjects were given a starting dose of 50 mg of sunitinib and were planned to be treated continuously for 28 days. The dosage of the drug was changed/the treatment plan was adjusted according to the toxic side effects that occurred in the patients after taking the drug.